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The health and economic effects of SARS-CoV-2 have been 
devastating to South Africa (SA). At the time of writing, the country 
is ill-prepared for mitigating a third wave, with only a minority of 
largely urban health workers being vaccinated against COVID-19 and 
roll-out to the general population yet to start. This despite SA being 
the first country on the continent to receive vaccines – 1 million 
AstraZeneca SARS-CoV-2 (AZ) vaccine doses on 1 February 2021.
We note with dismay the reselling of the AZ vaccines to the African 
Union[1] despite the B.1.351 variant, the dominant variant during SA’s 
second wave, circulating in much of Africa. We believe that SA has 
squandered the opportunity to protect at least half a million of its 
most vulnerable citizens before the next resurgence, with massive 
healthcare and economic cost. Alternatives to the AZ vaccine will not 
be available to South Africans within the next few months to make 
up the shortfall.
Why has there been a refusal in the National Department of Health 
(NDoH) and the Ministerial Advisory Committee on Vaccines 
(MAC-Vac) to use the AZ vaccine locally? The continued insistence 
by the NDoH and the MAC-Vac on not using it is out of step with 
recommendations by the World Health Organization (WHO) and 
other normative agencies, and the current state of vaccine science. [2,3] 
Unfortunately, none of the MAC-Vac’s advisories, rationales or 
decisions have been published in the public domain since 3 January 
2021, and none of the debate around specific vaccine choices has 
therefore been open to the public or the broader scientific community. 
From media interviews, the chief reason appears to be concern about 
the lower efficacy against the B.1.351 variant. This followed findings 
from a study conducted in SA that failed to demonstrate efficacy 
of >60% (the hypothesis being tested and for which the study was 
powered to address) against infection with COVID-19, after two 
vaccine doses.[4] The study demonstrated a 75% reduced risk of mild 
to moderate COVID-19 caused by the first-wave ancestry virus 14 
days after the first dose, but with no significant protection against 
mild to moderate disease caused by the B.1.351 variant after two 
doses of the vaccine. There were no severe COVID-19 cases in either 
the vaccine or the placebo arm, as the participants were young and 
largely healthy; this study was not suited to assess whether the AZ 
vaccine protects against severe disease, which is largely seen in older 
patients and those with serious comorbidities, whether caused by 
B.1.351 or any other variant. Animal challenge studies following AZ 
vaccination have reported 9-fold reduction in neutralising antibody 
activity against the B.1.351 variant relative to ancestry virus, similar 
to that observed for natural induced antibody following infection 
by prototype-like virus infection.[5] However, immunised animals 
were fully protected against severe lower respiratory tract infection 
following challenge by the variants.[6]
SA’s muddled procurement strategy is further demonstrated by 
the commitment to buy 20 million doses of the Pfizer vaccine, for 
which there is no clinical evidence of efficacy against the B.1.351 
variant. We agree with the decision to purchase the Pfizer vaccine, 
but the NDoH must concede that it then makes a mockery of the 
argument that we cannot use the AZ vaccine because of a lack of 
data against severe disease caused by this same B.1.351 variant. The 
Pfizer vaccine, like most other first-generation COVID-19 vaccines, 
is likely to confer high levels of protection against severe COVID-19, 
even caused by the B.1.351 variant. Nevertheless, laboratory testing 
has demonstrated 3-fold or more reduction of the vaccine-induced 
neutralising antibody against the B.1.1351 variant relative to activity 
against the ancestry virus, suggesting that there would be diminished 
protection against mild COVID-19 caused by the B.1.1351 variant. 
Intriguingly, SA has not included the Novavax vaccine as part of its 
roll-out strategy, despite this being the only COVID-19 vaccine to 
report on efficacy (49 - 60%) against mild to moderate COVID-19 
caused by the B.1.351 variant, and 100% protection against severe 
COVID-19.[7] The only other COVID-19 vaccine that SA has now 
committed to purchasing is the Johnson & Johnson (J&J) vaccine, 
for which efficacy against severe COVID-19 caused by the B.1.1351 
variant is 82%, while efficacy against mild illness caused by the 
B.1.351 variant is yet to be reported on. The Moderna, Sputnik V and 
Sinopharm vaccines, with no public commitment to procure by the 
NDoH, have similarly not had B.1.351 data reported.
To summarise the evidence, the AZ vaccine is extremely safe and 
provides near-total protection against severe COVID-19 caused 
by ancestry virus, much like other vaccines such as the J&J, Pfizer, 
Moderna, Novavax and Sputnik-V.[8,9] There are no published data 
on the Sinopharm vaccine, which is also widely used. Prior natural 
infection with SARS-CoV-2 is similarly highly protective against 
severe COVID-19,[10,11] while it may not protect against mild infection 
by the B.1.351 variant[7] (Fig. 1 and Table 1). Taken together, the 
data suggest that COVID-19 vaccines (or prior infection) may not 
provide sterilising immunity or protect against mild COVID-19 
caused by the B.1.351 variant, because of the relative resistance 
of this variant to antibody-neutralising activity. Nevertheless, the 
current first-generation spike-protein-based COVID-19 vaccines are 
likely to still confer substantial protection against severe disease,[13] 
because vaccine-induced CD8 (natural killer) cell responses are 
largely unaffected by mutations observed in the B.1.351 spike 
protein. It will be impossible to fully assess the impact of each 
COVID-19 vaccine against the B.1.351 variant and other similar 
variants that continue evolving, so we are reliant on a combination 
of immunogenicity studies, clinical trials, animal model challenge 
studies and observational data from mass vaccination programmes. [14] 
All data points suggest that the current first-generation COVID-19 
vaccines induce sufficient immunity to substantially reduce the risk 
of severe COVID-19, and no data suggest the contrary. Misguided 
comparisons of different endpoints from different studies, evaluated 
in different population demographics, done in different countries 
and at different times, have been used as evidence that the AZ vaccine 
may be inferior to other vaccines. Although the AZ vaccine does not 
reduce the risk of mild COVID-19 caused by the B.1.351 variant, even 
if the protection against severe disease and death afforded by the AZ 
vaccine ends up being just half or a third of what it is with comparator 
vaccines (a highly unlikely scenario), it is irresponsible to pass up 
the opportunity to reduce the number of deaths in the absence of 
alternative vaccines.
Where the AZ vaccine is in use, mortality in vaccinated populations 
has plummeted, including in the UK, home to its own more 
infectious and virulent B.1.1.7 variant.[15] The fact that ‘breakthrough’ 
infections by variants, causing hospitalisation and death, have not 
been reported in tens of millions of Europeans given the AZ vaccine, 
is highly reassuring.
Cost or a desire ‘not to waste money’ has been cited as a reason 
for delaying use and reselling of the AZ vaccine, an argument 
comprehensively disputed when matched against the cost of infection 
This open-access article is distributed under 
Creative Commons licence CC-BY-NC 4.0.
South Africa should be using all the COVID-19 vaccines 
available to it – urgently
2       Published online ahead of print
EDITORIAL
and lockdowns on the economy.[16-18] SA lost ~8.2% (ZAR389 billion) 
of its gross domestic product in 2020 as a result of the COVID-
19 pandemic. The cost (depending on which vaccine we use) of 
vaccinating everyone who needs it, is between ZAR8.6 and ZAR16.4 
billion.[18]
Finally, sending the AZ vaccine to other African countries raises 
deep ethical concerns. The B.1.351 variant has been detected 
throughout Africa and may be responsible for the devastating second 
wave many countries have just experienced.[19,20] If the SA authorities 
truly believed that the AZ vaccine did not work, why was it sold on to 
the African Union, and why would they purchase it?
Arguments about undermining vaccine confidence by not 
rolling out the perfect vaccine are misguided in terms of public 
health. SARS-CoV-2 spreads quickly, with unpredictable waves but 
predictable consequences. Speed of the vaccination programme is far 
more important than getting the perfect vaccine. The ‘abundance of 
caution’ argument ventured by members of the SA government, the 
MAC-Vac and European governments, when dealing with efficacy 
and recent reported thrombotic side-effects of the AZ vaccine, 
has already seen the vaccine labelled ‘second best’, with reports of 
AZ-specific vaccine hesitance from around the globe. To be clear: 
the AZ vaccine is safe, and based on all known information, will be 
sufficiently effective in stopping the endpoints we care about most – 
hospitalisation and death.
We understand that a decision like this is complex, but as the 
reasoning behind it has not been made public, we are at a loss to 
explain the government’s action. Politicians and advisory boards need 
to be transparent and explain decisions, and, if necessary, reverse 
them. If the NDoH, the MAC-Vac or the regulator have access to new 
information, this needs to be made public. Transparency is critical 
to trust in public health. Currently, SA has misapplied standards 
hampering the rollout of a vital and available tool to mitigate the 
epidemic. Moreover, it has gone against guidance from the WHO.[2]
We do not have the luxury of choice or time. All the vaccines provide 
Fig. 1. Description of six SARS-Cov-2 vaccine clinical studies (adapted from figure provided by Dr Monica Gandhi,[12] used with permission).
Table 1. Description of six SARS-Cov-2 vaccines against variants
Reduction of neutralising activity 
in laboratory assays
Clinical efficacy against the 
B.1.351 variant
Clinical efficacy against 
ancestral variant
Pfizer 3 - 42× Unknown 95%
Moderna 6 - 28× Unknown 94.1%
AstraZeneca 3.5 - 21×/undetectable 10% (mild to moderate) 70.4%
Gamaleya (Sputnik-V) Unknown Unknown 91.6%
Johnson & Johnson Pending 64% (moderate to severe)
82% (severe)
72% (moderate to severe disease)
Novavax Pending 49% (including HIV; mild to 
moderate)




Sinopharm 1.6× Unknown 79 - 86%
Sinovac Unknown Unknown 50.4%
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better protection against severe disease than against mild disease. 
The AZ vaccine should be regarded as sufficient to prevent at least a 
substantial proportion of the most severe health outcomes of SARS-
CoV-2 infection until data are produced to the contrary. Rapidly 
rolling out COVID-19 vaccine to our population at risk of severe 
disease and death is the most important strategic intervention to save 
lives, livelihoods and SA’s health system and reducing the devastating 
effects of a third wave of COVID-19.
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